Legal status by country
Is Relaxin-2 legal?
Written by Aaron CuhaReviewed Sep 2026
How Relaxin-2 is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Not a medicine; endogenous signalling molecule | Not a medicine; endogenous signalling molecule | Not a medicine; endogenous signalling molecule | Not a medicine; endogenous signalling molecule |
| Note | Relaxin-2 is a hormone produced by the corpus luteum and placenta. Its recombinant form, serelaxin, is not FDA-approved: RELAX-AHF-2 missed both primary endpoints in 6,545 patients and development for acute heart failure stopped. No approved medicine acts at RXFP1. Long-acting relaxin fusions such as AZD3427 remain investigational. | No licensed relaxin medicine. Serelaxin was not authorised after the confirmatory phase 3 trial failed. | No registered relaxin medicine. | No approved relaxin medicine. |
US FDA status: Relaxin-2 is an endogenous hormone. Serelaxin, its recombinant form, is not approved by the FDA or any other regulator. It received attention after the RELAX-AHF result but the confirmatory RELAX-AHF-2 trial failed both primary endpoints and development for acute heart failure was discontinued.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.